MedTrace Logo

The Effective and Safety of Thalidomide in NTDT

NCT02995707 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-03-22

No results posted yet for this study

Summary

This is an exploratory experiment, aims to explore the effective and safety of thalidomide in the treatment of NTDT to improve the hemoglobin level, improve the quality of life, reduce blood transfusion, so as to avoid the adverse reactions caused by transfusion.15\~30 patients will be enrolled, including type α 5\~13 cases, type β 10\~17 cases.

Conditions

Interventions

DRUG

Thalidomide

thalidomide:50mg/d p.o at bedtime

Sponsors & Collaborators

  • Xiao-Lin Yin

    lead OTHER

Principal Investigators

  • Yin X Lin, director · NO.3 Hospital of the Chinese People's Liberation Army

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-12-31
Completion
2018-03-31

Countries

  • China

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02995707 on ClinicalTrials.gov